Journals / MN Oftalmoloji / 2017 / Cilt: 24 - Sayı: 3

Intravitreal Aflibercept Injection Treatment for Resistant Pigment Epithelial Detachment Cases

Tedaviye Dirençli Pigment Epitel Dekolmanı Olgularında Vitreus İçine Aflibersept Enjeksiyonu

Pages
160–164
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Switching to aflibercept presents satisfactory functional and anatomical outcomes with a reasonable complication rate in treatment-resistant pigment epithelial detachment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the efficacy and safety of switching from ranibizumab to aflibercept intravitreal injections in treatment for resistant retinal pigment epithelial detachment cases.
📊
Key Findings & Data:Material and Method: The datas of intravitreal ranibizumab treatment-resistant 18 eyes of 18 patients those have been switched to aflibercept treatment were reviewed retrospectively.
💡
Conclusion & Impact:Conclusion: Switching to aflibercept presents satisfactory functional and anatomical outcomes with a reasonable complication rate in treatment-resistant pigment epithelial detachment.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate the efficacy and safety of switching from ranibizumab to aflibercept intravitreal injections in treatment for resistant retinal pigment epithelial detachment cases. Material and Method: The datas of intravitreal ranibizumab treatment-resistant 18 eyes of 18 patients those have been switched to aflibercept treatment were reviewed retrospectively. After three monthly injections, bimonthly regimen was performed. The changes of pigment epithelial detachment height and radius, and the best-corrected visual acuity were analyzed retrospectively. Results were considered statistically significant as p<0.05. Results: Mean baseline pigment epithelial detachment height decreased from 283±145 to 132±4253 micron at month 12 (p=0.0008). Mean baseline pigment epithelial detachment radius decreased from 2413±756 to 1756±812 micron at month 12 (p=0.0007). Complete pigment epithelial detachment resolution occurred in two of the patients at the end of the 12 months. Baseline est-corrected visual acuity improved from 0.68±0.32 to 0.48±0.21 logMar (p=0.005). Conclusion: Switching to aflibercept presents satisfactory functional and anatomical outcomes with a reasonable complication rate in treatment-resistant pigment epithelial detachment.

Özet

Amaç: Tedaviye dirençli retina pigment epiteli dekolmanı olgularında vitreus içine ranibizumab enjeksiyonundan aflibersept tedavisine geçişin etkinlik ve güvenilirliğini değerlendirmek. Gereç ve Yöntem: Ranibizumab tedavisine dirençli olup, aflibersept tedavisine geçilmiş olan 18 hastanın 18 gözünün bulguları retrospektif olarak tarandı. 3 ay boyunca aylık enjeksiyondan sonra 2 ayda bir enjeksiyon yapıldı. Pigment epitel dekolmanı yükseklik ve çapındaki değişimler ve düzeltilmiş en iyi görme keskinliğindeki değişimler değerlendirildi. p<0,05 ise sonuçlar istatistiksel olarak anlamlı kabul edildi. Bulgular: Aflibersept öncesi 283 ± 145 mikron olan pigment epitel dekolmanı yüksekliği, 132±53 mikrona düştü (p=0,008). Aflibersept öncesi 2413±756 mikron olan pigment epitel dekolmanı çapı, 1756 ± 812 mikrona düştü (p=0,007). 12 ay sonunda tam düzelme sağlanan 2 hastamız oldu. Aflibersept öncesi 0,68 ± 0,32 logMAR olan görme keskinliği, 0,48±0,21 logMAR'a yükseldi (p=0,005).Sonuç: Tedaviye dirençli pigment epitel dekolmanı vakalarında aflibersepte dönüş, maküla komplikasyon oranları ile beraber, fonksiyonelve anatomik olarak tatmin edici sonuçlar sunmaktadır.

🔖

Cite This Article

KAYA, F., BAYBORA, H., KOÇ, H. (2017). Intravitreal Aflibercept Injection Treatment for Resistant Pigment Epithelial Detachment Cases. MN Oftalmoloji, Cilt: 24 - Sayı: 3, 160–164. https://ajindex.com/articles/295478

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Zayit-Soudry S, Moroz I, Loewenstein A. Retinal pigment epithelial detachment. Surv Ophthalmol 2007;52:227-43
  2. Roquet W, Roudot-Thoraval F, Coscas G, Soubrane G. Clinical features of drusenoid pigment epithelial detachment in age related macular degeneration. Br J Ophthalmol 2004;88:638-42
  3. Iordanous Y, Powell AM, Mao A. et al. Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration. Can J Ophthalmol 2014;49: 367-76
  4. Ünal M. Duyu Retina ve Retina Pigment Epitelinin Seröz Dekolmanı. T Klin J Ophthalmol 1992;1:298-303 5. Mrejen S, Sarraf D, Mukkamala SK, Freund KB. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina 2013;33:1735-62
  5. Yannuzzi LA. Retinal pigment epithelial detachment. J Fr Ophtalmol 1989;12:761-74
  6. Gelisken F. Inhoffen W. Partsch M. et al. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 2001;131:518-520 8. Weinberger AW, Thiel M, Mohammadi B. et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 2007;144:294-296 9. Brown DM, Kaiser PK, Michels M. ANCHOR Study Group et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44 10. Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31 11. Fung AE, Lalwani GA, Rosenfeld PJ. et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83 12. Broadhead GK, Hong T, Zhu M, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina 2015;35:975-81
  7. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF. et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthal mo - logy 2014;121:193-201
  8. Kumar N, Marsiglia M, Mrejen S. et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013;33:1605-12 15. Patel KH, Chow CC, Rathod R. et a